Pub Date : 2023-08-31eCollection Date: 2023-12-01DOI: 10.31138/mjr.310823.tio
Maria Stavrakidou, Maria Trachana, Artemis Koutsonikoli, Kyriaki Spanidou, Alexandra Hristara-Papadopoulou
Objectives: To investigate the applicability and impact of a physiotherapy tele-rehabilitation program (TRP) on children with Juvenile Idiopathic Arthritis (JIA) and their families.
Methods: Thirty JIA patients, applying an individualized home-exercise program (HEP), were randomly divided in the tele-rehabilitation (TRG, n=15) and control group (CG, n=15). Each TRG patient participated in a 30-minute tele-session, under a paediatric physiotherapist's supervision, twice a week, for 12 weeks. Before and after the TRP (T1 and T2, respectively), all participants and a parent/guardian completed the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) questionnaire and a questionnaire regarding the HEP implementation and compliance. Residual disease was estimated at T1 and T2. At T2, TRG patients/parents completed a questionnaire evaluating the TRP. One month after T2, a reassessment of compliance with the HEP was performed.
Results: The patients' median age was 12.8 (8-16) years. At T2, the TRG patients performed the HEP significantly more frequently (p=0.023), for a longer time (p=0.034) and with less urging (p=0.004), compared to T1. Moreover, they exhibited significantly increased compliance with HEP (p=0.001), better functionality (p=0.008), better quality of life (p=0.007) and less pain (p=0.017). The CG patients showed no significant changes. Residual disease improved in both groups (TRG:p=0.002, CG:p=0.018), but more in the TRG (p=0.045). TRP's applicability and total benefit were rated as excellent by patients/parents. Finally, one month after T2, compliance with the HEP was still greater than at T1(p=0.001).
Conclusion: An interactive physiotherapy TRP can be implemented effectively for JIA patients, providing an additional tool for their rehabilitation.
目的研究物理治疗远程康复计划(TRP)对青少年特发性关节炎(JIA)患儿及其家庭的适用性和影响:30名JIA患者采用个性化家庭锻炼计划(HEP),随机分为远程康复组(TRG,15人)和对照组(CG,15人)。在儿科物理治疗师的指导下,每名 TRG 患者参加一次 30 分钟的远程治疗,每周两次,持续 12 周。在TRP之前和之后(分别为T1和T2),所有参与者和一名家长/监护人填写了青少年关节炎多维评估报告(JAMAR)问卷以及一份关于HEP实施情况和依从性的问卷。在T1和T2时对残余疾病进行了估计。在第二阶段,TRG 患者/家长填写了一份评估 TRP 的问卷。T2结束一个月后,对HEP的依从性进行重新评估:结果:患者的中位年龄为 12.8(8-16)岁。与 T1 相比,TRG 患者在 T2 进行 HEP 的频率明显增加(p=0.023),时间明显延长(p=0.034),催促次数明显减少(p=0.004)。此外,他们对 HEP 的依从性(p=0.001)、功能性(p=0.008)、生活质量(p=0.007)和疼痛感(p=0.017)都明显提高。CG患者则无明显变化。两组患者的残余疾病均有所改善(TRG:p=0.002,CG:p=0.018),但TRG患者的改善更大(p=0.045)。患者/家长对 TRP 的适用性和总体疗效给予了极高的评价。最后,T2期一个月后,患者对HEP的依从性仍高于T1期(p=0.001):结论:交互式物理治疗 TRP 可以有效地用于 JIA 患者,为他们的康复提供额外的工具。
{"title":"The Impact of a Physiotherapy Tele-Rehabilitation Program on the Quality of Care for Children with Juvenile Idiopathic Arthritis.","authors":"Maria Stavrakidou, Maria Trachana, Artemis Koutsonikoli, Kyriaki Spanidou, Alexandra Hristara-Papadopoulou","doi":"10.31138/mjr.310823.tio","DOIUrl":"10.31138/mjr.310823.tio","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the applicability and impact of a physiotherapy tele-rehabilitation program (TRP) on children with Juvenile Idiopathic Arthritis (JIA) and their families.</p><p><strong>Methods: </strong>Thirty JIA patients, applying an individualized home-exercise program (HEP), were randomly divided in the tele-rehabilitation (TRG, n=15) and control group (CG, n=15). Each TRG patient participated in a 30-minute tele-session, under a paediatric physiotherapist's supervision, twice a week, for 12 weeks. Before and after the TRP (T1 and T2, respectively), all participants and a parent/guardian completed the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) questionnaire and a questionnaire regarding the HEP implementation and compliance. Residual disease was estimated at T1 and T2. At T2, TRG patients/parents completed a questionnaire evaluating the TRP. One month after T2, a reassessment of compliance with the HEP was performed.</p><p><strong>Results: </strong>The patients' median age was 12.8 (8-16) years. At T2, the TRG patients performed the HEP significantly more frequently (p=0.023), for a longer time (p=0.034) and with less urging (p=0.004), compared to T1. Moreover, they exhibited significantly increased compliance with HEP (p=0.001), better functionality (p=0.008), better quality of life (p=0.007) and less pain (p=0.017). The CG patients showed no significant changes. Residual disease improved in both groups (TRG:p=0.002, CG:p=0.018), but more in the TRG (p=0.045). TRP's applicability and total benefit were rated as excellent by patients/parents. Finally, one month after T2, compliance with the HEP was still greater than at T1(p=0.001).</p><p><strong>Conclusion: </strong>An interactive physiotherapy TRP can be implemented effectively for JIA patients, providing an additional tool for their rehabilitation.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"34 4","pages":"443-453"},"PeriodicalIF":0.0,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10815514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We encountered five patients with Rheumatic symptoms, suspected to have five different clinical diagnoses: Systemic vasculitis, Gout, Systemic Sclerosis, Rheumatoid Arthritis, and Spondyloarthropathy. However, all were finally diagnosed with the same illness: Hansen's Disease.
{"title":"Hansen's Disease, the Perpetual Impersonator (\"The Behroopiya\") of Rheumatology Practice: A Case Series.","authors":"Kavita Krishna, Sandeep Sadashivrao Kansurkar, Akanksha Kapoor, Sri Lakshmi Sathiyaseelan, Deepti Agarwal","doi":"10.31138/mjr.310823.hdt","DOIUrl":"10.31138/mjr.310823.hdt","url":null,"abstract":"<p><p>We encountered five patients with Rheumatic symptoms, suspected to have five different clinical diagnoses: Systemic vasculitis, Gout, Systemic Sclerosis, Rheumatoid Arthritis, and Spondyloarthropathy. However, all were finally diagnosed with the same illness: Hansen's Disease.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"34 4","pages":"544-546"},"PeriodicalIF":0.0,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10815521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-29eCollection Date: 2023-12-01DOI: 10.31138/mjr.290823.hsr
Tayyeba Khursheed, Ahmed Masood, Muhammad Sufyan Khan, Muhammad Sharif, Somaya Shah, Muhammad Arqam Miraj
Hughes-Stovin Syndrome (HSS) is a rare vasculitic disorder characterised by widespread pulmonary artery aneurysms. It shares some features with Behçet disease. Currently, the diagnosis is based on clinical suspicion. Our case describes a young male who presented with haemoptysis and previous history of pulmonary embolism. Workup was essentially unremarkable, but imaging revealed multiple pulmonary artery aneurysms. Timely initiation of glucocorticoids and immunosuppression with cyclophosphamide led to improvement. High-dose glucocorticoids and immunosuppressants are the mainstays of treatment. Untreated cases can result in fatal outcomes.
{"title":"Hughes-Stovin Syndrome: A Case Report on a Rare, Life-Threatening Vasculitis.","authors":"Tayyeba Khursheed, Ahmed Masood, Muhammad Sufyan Khan, Muhammad Sharif, Somaya Shah, Muhammad Arqam Miraj","doi":"10.31138/mjr.290823.hsr","DOIUrl":"10.31138/mjr.290823.hsr","url":null,"abstract":"<p><p>Hughes-Stovin Syndrome (HSS) is a rare vasculitic disorder characterised by widespread pulmonary artery aneurysms. It shares some features with Behçet disease. Currently, the diagnosis is based on clinical suspicion. Our case describes a young male who presented with haemoptysis and previous history of pulmonary embolism. Workup was essentially unremarkable, but imaging revealed multiple pulmonary artery aneurysms. Timely initiation of glucocorticoids and immunosuppression with cyclophosphamide led to improvement. High-dose glucocorticoids and immunosuppressants are the mainstays of treatment. Untreated cases can result in fatal outcomes.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"34 4","pages":"565-569"},"PeriodicalIF":0.0,"publicationDate":"2023-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10815522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-29eCollection Date: 2023-12-01DOI: 10.31138/mjr.290823.ib
Elif Gur Kabul, Sinem Yenil, Firdevs Ulutas, Bilge Basakci Calik, Veli Cobankara
Objective: The aim of this study was to compare the effects of Behçet's disease in terms of anxiety, biopsychosocial status, fatigue, sleep quality, alexithymia, cognitive level, and quality of life according to major and minor organ involvement.
Methods: The study was planned as a single-centre cohort study. Fifty patients diagnosed with Behçet's (mean age 43±11.96 years) were included in the study. The patients were divided into two groups as major organ involvement (uveitis, neuro-Behçet's, or vascular type Behçet's disease) and minor organ involvement (mucocutaneous type Behçet's disease). Biopsychosocial status was evaluated with Biopsychosocial Questionnaire (BETY-BQ), anxiety with Beck Anxiety Inventory (BAI), fatigue with Multidimensional Assessment of Fatigue (MAF) Scale, sleep quality with Pittsburgh Sleep Quality Index (PSQI), alexithymia with Toronto Alexithymia Scale-20 (TAS-20), cognition level with Mini-Mental State Examination (MMSE), and quality of life with Short Form-36 (SF-36).
Results: In the comparison according to minor and major organ involvement, there was no significant difference between the groups in BETY-BQ, BAI, MAF, PSQI, TAS-20, MMSE and SF-36 (p>0.05).
Conclusion: Behçet's disease negatively effects in parameters such as biopsychosocial status, fatigue, sleep quality, alexithymia and quality of life. The presence of major or minor organ involvement in the patients did not change these negative effects.
{"title":"Investigation of Biopsychosocial Status, Fatigue, Sleep Quality, Alexithymia, Cognitive Functions, and Quality of Life in Behçet's Disease.","authors":"Elif Gur Kabul, Sinem Yenil, Firdevs Ulutas, Bilge Basakci Calik, Veli Cobankara","doi":"10.31138/mjr.290823.ib","DOIUrl":"10.31138/mjr.290823.ib","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to compare the effects of Behçet's disease in terms of anxiety, biopsychosocial status, fatigue, sleep quality, alexithymia, cognitive level, and quality of life according to major and minor organ involvement.</p><p><strong>Methods: </strong>The study was planned as a single-centre cohort study. Fifty patients diagnosed with Behçet's (mean age 43±11.96 years) were included in the study. The patients were divided into two groups as major organ involvement (uveitis, neuro-Behçet's, or vascular type Behçet's disease) and minor organ involvement (mucocutaneous type Behçet's disease). Biopsychosocial status was evaluated with Biopsychosocial Questionnaire (BETY-BQ), anxiety with Beck Anxiety Inventory (BAI), fatigue with Multidimensional Assessment of Fatigue (MAF) Scale, sleep quality with Pittsburgh Sleep Quality Index (PSQI), alexithymia with Toronto Alexithymia Scale-20 (TAS-20), cognition level with Mini-Mental State Examination (MMSE), and quality of life with Short Form-36 (SF-36).</p><p><strong>Results: </strong>In the comparison according to minor and major organ involvement, there was no significant difference between the groups in BETY-BQ, BAI, MAF, PSQI, TAS-20, MMSE and SF-36 (p>0.05).</p><p><strong>Conclusion: </strong>Behçet's disease negatively effects in parameters such as biopsychosocial status, fatigue, sleep quality, alexithymia and quality of life. The presence of major or minor organ involvement in the patients did not change these negative effects.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"34 4","pages":"436-442"},"PeriodicalIF":0.0,"publicationDate":"2023-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10815526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-29eCollection Date: 2023-12-01DOI: 10.31138/mjr.290823.sja
Takashi Nawata, Masafumi Yano
{"title":"Sternoclavicular Joint Arthritis in a Patient with Psoriatic Arthritis.","authors":"Takashi Nawata, Masafumi Yano","doi":"10.31138/mjr.290823.sja","DOIUrl":"10.31138/mjr.290823.sja","url":null,"abstract":"","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"34 4","pages":"575-576"},"PeriodicalIF":0.0,"publicationDate":"2023-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10815531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-29eCollection Date: 2024-03-01DOI: 10.31138/mjr.140523.aso
Artemis Koutsonikoli, Anna Taparkou, Polyxeni Pratsidou-Gertsi, Vasiliki Sgouropoulou, Maria Trachana
Objectives: To investigate the immunoregulatory role of the Programmed-cell-Death-protein-1 (PD1) pathway, an inhibitory immune checkpoint, in Juvenile Idiopathic Arthritis (JIA).
Methods: The PD1 expression on CD4+ and CD8+ T-cells was determined by flow cytometry and the PD1 soluble form (sPD1) levels by ELISA, in peripheral blood (PB)/serum and synovial fluid (SF) samples of JIA patients and healthy controls (HCs). We searched for any association in-between the biomarkers and with JIA activity.
Results: 101 Caucasian patients (69 female), aged 12 (8-15) years, and 20 HCs participated in this study. The PB PD1 expression on T-cells was higher in: a. JIA patients vs HCs (CD4: 1.24% vs 0.32%, p=0.007, CD8: 1.6% vs 0.4%, p=0.002). b. active vs inactive JIA (CD4: 1.44% vs 0.87%, p=0.072, CD8: 2.1% vs 0.93%, p=0.005). The SF PD1 expression on T-cells correlated strongly and positively with the disease activity (CD4: ρ=0.55, p=0.022, CD8: ρ=0.555, p=0.026). The SF PD1 expression on CD8 T-cells was higher in patients on-treatment vs those off-treatment (21.3% vs 5.83% p=0.004). The sPD1 levels were higher in the SF vs the serum (801pg/ml vs 367.2, p=0.013), without an association with disease activity.
Conclusion: These results indicate an up-regulation of the PD1-pathway in JIA, at least quantitatively, especially in active disease. sPD1 is compartmentally produced at the inflamed joints. Further investigation in a larger sample of JIA patients may verify these observations and contribute to unravelling the precise role of the PD1 pathway in the pathogenesis and persistence of the joint inflammation.
研究目的研究程序性细胞死亡蛋白-1(PD1)通路(一种抑制性免疫检查点)在青少年特发性关节炎(JIA)中的免疫调节作用:方法:在JIA患者和健康对照组(HCs)的外周血(PB)/血清和滑液(SF)样本中,通过流式细胞术测定CD4+和CD8+T细胞上的PD1表达,通过ELISA测定PD1可溶性形式(sPD1)的水平。我们研究了这些生物标志物与 JIA 活动之间的关联:101名年龄在12(8-15)岁的白种人患者(69名女性)和20名健康对照者参与了这项研究。a. JIA 患者 vs HCs(CD4:1.24% vs 0.32%,p=0.007;CD8:1.6% vs 0.4%,p=0.002);b. 活动性 vs 非活动性 JIA(CD4:1.44% vs 0.87%,p=0.072;CD8:2.1% vs 0.93%,p=0.005)。T 细胞上的 SF PD1 表达与疾病活动性密切正相关(CD4:ρ=0.55,p=0.022;CD8:ρ=0.555,p=0.026)。接受治疗的患者与未接受治疗的患者相比,CD8 T 细胞上的 SF PD1 表达量更高(21.3% vs 5.83% p=0.004)。SF与血清中的sPD1水平相比更高(801pg/ml vs 367.2,p=0.013),但与疾病活动无关:这些结果表明,PD1通路在JIA中上调,至少是定量上调,尤其是在疾病活动期。对更大样本的 JIA 患者进行进一步调查可能会验证这些观察结果,并有助于揭示 PD1 通路在关节炎症的发病机制和持续存在中的确切作用。
{"title":"A Study on the Immunoregulatory Role of the PD1 Pathway in Juvenile Idiopathic Arthritis.","authors":"Artemis Koutsonikoli, Anna Taparkou, Polyxeni Pratsidou-Gertsi, Vasiliki Sgouropoulou, Maria Trachana","doi":"10.31138/mjr.140523.aso","DOIUrl":"10.31138/mjr.140523.aso","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the immunoregulatory role of the Programmed-cell-Death-protein-1 (PD1) pathway, an inhibitory immune checkpoint, in Juvenile Idiopathic Arthritis (JIA).</p><p><strong>Methods: </strong>The PD1 expression on CD4+ and CD8+ T-cells was determined by flow cytometry and the PD1 soluble form (sPD1) levels by ELISA, in peripheral blood (PB)/serum and synovial fluid (SF) samples of JIA patients and healthy controls (HCs). We searched for any association in-between the biomarkers and with JIA activity.</p><p><strong>Results: </strong>101 Caucasian patients (69 female), aged 12 (8-15) years, and 20 HCs participated in this study. The PB PD1 expression on T-cells was higher in: a. JIA patients <i>vs</i> HCs (CD4: 1.24% <i>vs</i> 0.32%, p=0.007, CD8: 1.6% <i>vs</i> 0.4%, p=0.002). b. active <i>vs</i> inactive JIA (CD4: 1.44% <i>vs</i> 0.87%, p=0.072, CD8: 2.1% <i>vs</i> 0.93%, p=0.005). The SF PD1 expression on T-cells correlated strongly and positively with the disease activity (CD4: ρ=0.55, p=0.022, CD8: ρ=0.555, p=0.026). The SF PD1 expression on CD8 T-cells was higher in patients on-treatment <i>vs</i> those off-treatment (21.3% <i>vs</i> 5.83% p=0.004). The sPD1 levels were higher in the SF <i>vs</i> the serum (801pg/ml <i>vs</i> 367.2, p=0.013), without an association with disease activity.</p><p><strong>Conclusion: </strong>These results indicate an up-regulation of the PD1-pathway in JIA, at least quantitatively, especially in active disease. sPD1 is compartmentally produced at the inflamed joints. Further investigation in a larger sample of JIA patients may verify these observations and contribute to unravelling the precise role of the PD1 pathway in the pathogenesis and persistence of the joint inflammation.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 1","pages":"134-142"},"PeriodicalIF":0.0,"publicationDate":"2023-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11082771/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140912902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tofacitinib, a Janus kinase inhibitor, has been recently investigated as a potential therapy for refractory scleritis. Despite treatment with systemic immunosuppressive agents, scleritis is refractory to conventional therapy in a significant number of patients. Hereby, we report the use of tofacitinib as a steroid-sparing immunomodulatory agent in three patients with refractory scleritis who were either recalcitrant or intolerant to conventional therapy.
{"title":"Tofacitinib in Refractory Scleritis: A Case Series.","authors":"Suvankar Dey, Rajdeep Sarkar, Amrita Pradhan, Prasanta Padhan, Debashis Maikap","doi":"10.31138/mjr.20230828.ti","DOIUrl":"10.31138/mjr.20230828.ti","url":null,"abstract":"<p><p>Tofacitinib, a Janus kinase inhibitor, has been recently investigated as a potential therapy for refractory scleritis. Despite treatment with systemic immunosuppressive agents, scleritis is refractory to conventional therapy in a significant number of patients. Hereby, we report the use of tofacitinib as a steroid-sparing immunomodulatory agent in three patients with refractory scleritis who were either recalcitrant or intolerant to conventional therapy.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"34 3","pages":"367-371"},"PeriodicalIF":0.0,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71522814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: We report a longitudinal observational cohort of idiopathic inflammatory myositis (IIM) focusing on the long-term clinical outcome and associated parameters.
Methods: IIM patients were classified as per Bohan and Peter criteria. In those with ≥ 24 months of follow-up; the treatment response, functional outcomes, and damage at last follow-up were recorded. Complete clinical response and clinical remission as defined by Oddis et al., was used to define outcomes at last follow-up.
Results: The cohort consists of 175 patients, mean age 40.9 (+12.6) years, M:F 1:3.3; and the major subsets were dermatomyositis (44.6%), overlap myositis (25.7%), antisynthetase syndrome (6.3%), polymyositis (14.3%), and juvenile DM/OM (8.6%). Ninety-four patients have followed up for 24 months or more, with the median (IQR) of 65(35,100.7) months. Of them, 74.1% and 11.8% had complete and partial clinical responses respectively at the last follow-up. In our cohort 40.2% were off-steroids and 13.8% were in clinical remission at the last follow-up. Complete clinical response was associated with better functional outcomes and lesser damage as determined by HAQ-DI of 0[OR10.9; 95%CI (3.3,160)], MRS [OR 3.2; 95%CI (1.4,7.3)] and lesser MDI [OR 1.7; 95% CI (1.1,2.7)] respectively as compared to partial response (unadjusted analysis). Baseline parameters and IIM subsets did not significantly influence the functional outcome and damage. The mortality rate in our cohort is 24/175 (13.7%), the disease-specific mortality rate being 9.1%. Large majority of deaths were early, associated with active disease.
Conclusion: We report good long-term outcomes in all major myositis subsets. Partial clinical response to treatment is associated with worse functional outcomes and damage accrual. Death occurs early in association with active disease.
{"title":"Long Term Outcomes in Idiopathic Inflammatory Myositis: An Observational Epidemiologic Study over 15 Years.","authors":"Ramya Janardana, Sangeetha Kn, Vasudha Bhat, Divya Balakrishnan, John Michael Raj, Benzeeta Pinto, Chanakya K, Raghunandan Nadig, Anita Mahadevan, Vineeta Shobha","doi":"10.31138/mjr.280823.lto","DOIUrl":"10.31138/mjr.280823.lto","url":null,"abstract":"<p><strong>Background: </strong>We report a longitudinal observational cohort of idiopathic inflammatory myositis (IIM) focusing on the long-term clinical outcome and associated parameters.</p><p><strong>Methods: </strong>IIM patients were classified as per Bohan and Peter criteria. In those with ≥ 24 months of follow-up; the treatment response, functional outcomes, and damage at last follow-up were recorded. Complete clinical response and clinical remission as defined by Oddis et al., was used to define outcomes at last follow-up.</p><p><strong>Results: </strong>The cohort consists of 175 patients, mean age 40.9 (+12.6) years, M:F 1:3.3; and the major subsets were dermatomyositis (44.6%), overlap myositis (25.7%), antisynthetase syndrome (6.3%), polymyositis (14.3%), and juvenile DM/OM (8.6%). Ninety-four patients have followed up for 24 months or more, with the median (IQR) of 65(35,100.7) months. Of them, 74.1% and 11.8% had complete and partial clinical responses respectively at the last follow-up. In our cohort 40.2% were off-steroids and 13.8% were in clinical remission at the last follow-up. Complete clinical response was associated with better functional outcomes and lesser damage as determined by HAQ-DI of 0[OR10.9; 95%CI (3.3,160)], MRS [OR 3.2; 95%CI (1.4,7.3)] and lesser MDI [OR 1.7; 95% CI (1.1,2.7)] respectively as compared to partial response (unadjusted analysis). Baseline parameters and IIM subsets did not significantly influence the functional outcome and damage. The mortality rate in our cohort is 24/175 (13.7%), the disease-specific mortality rate being 9.1%. Large majority of deaths were early, associated with active disease.</p><p><strong>Conclusion: </strong>We report good long-term outcomes in all major myositis subsets. Partial clinical response to treatment is associated with worse functional outcomes and damage accrual. Death occurs early in association with active disease.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"34 4","pages":"513-524"},"PeriodicalIF":0.0,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10815524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: The aim of this study was to assess the association between the anthropometric/adiposity indices or ratios with the status of quality of life (QoL) in rheumatoid arthritis (RA) patients.
Methods: This study was carried out in the Rizgary Teaching Hospital in the Kurdistan Region of Iraq between 1st December 2021 and 31st March 2022. Seventy-five women with a mean value of 11.3 years' duration of disease were included in this study. The data relating to the demographic characteristics, disease activity score (DAS-28), biochemical measurements of the rheumatic profile, and anthropometric/adiposity indices and the ratios were included. The QoL of each patient was assessed using the WHOQOL-BREF.
Results: The mean ± SD of the age and duration of disease were 49.6± 12.0, and 11.3±8.4 year. 70 out of 75 (93.3%) patients have a DAS-28 score of >2.6. The median values of the transform scores of the WHOQOL-BREF domains were less than 50. There were significant inverse correlations between BMI, and waist-to-height ratio with physical activity (r = -0.167, p = 0.05, and r = -0.168, p = 0.05, respectively). Social domain was significantly and inversely correlated with waist-to-hip, estimated total body fat, and waist-adjusted weight index. A higher BMI and a lower hip index were associated significantly with a lower mean scores of physical health.
Conclusion: In RA patients, obesity is frequently observed. Over-weight and obese patients had a significantly lower mean score of physical health.
研究目的本研究旨在评估类风湿关节炎(RA)患者的人体测量/肥胖指数或比率与生活质量(QoL)之间的关系:本研究于 2021 年 12 月 1 日至 2022 年 3 月 31 日在伊拉克库尔德斯坦地区的里兹加里教学医院进行。75名妇女参与了这项研究,她们的平均病程为11.3年。研究纳入了与人口统计学特征、疾病活动评分(DAS-28)、风湿病生化测量、人体测量/肥胖指数和比率有关的数据。使用 WHOQOL-BREF 对每位患者的 QoL 进行了评估:年龄和病程的平均值(±SD)分别为 49.6±12.0 岁和 11.3±8.4 年。75 位患者中有 70 位(93.3%)的 DAS-28 评分大于 2.6。WHOQOL-BREF 各领域转换得分的中位值均低于 50。体重指数(BMI)和腰围身高比与体力活动呈明显的反向相关(分别为 r = -0.167,p = 0.05 和 r = -0.168,p = 0.05)。社会领域与腰臀比、估计体脂总量和腰围调整体重指数呈明显的反向相关。较高的体重指数和较低的臀围指数与较低的身体健康平均得分明显相关:结论:在 RA 患者中,肥胖是常见现象。结论:在 RA 患者中,肥胖症很常见,超重和肥胖患者的身体健康平均得分明显较低。
{"title":"Association Between the Quality of Life Domains with Anthropometric and Adiposity Indices in Rheumatoid Arthritis: A Cross-Sectional Study from a Single Centre in Erbil-Iraq.","authors":"Aryan Mohamadfatih Jalal, Zhala Kakamin Mawlood, Sheelan Faroz Aref, Marwan Salih Al-Nimer","doi":"10.31138/mjr.230828.jaa","DOIUrl":"https://doi.org/10.31138/mjr.230828.jaa","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to assess the association between the anthropometric/adiposity indices or ratios with the status of quality of life (QoL) in rheumatoid arthritis (RA) patients.</p><p><strong>Methods: </strong>This study was carried out in the Rizgary Teaching Hospital in the Kurdistan Region of Iraq between 1<sup>st</sup> December 2021 and 31<sup>st</sup> March 2022. Seventy-five women with a mean value of 11.3 years' duration of disease were included in this study. The data relating to the demographic characteristics, disease activity score (DAS-28), biochemical measurements of the rheumatic profile, and anthropometric/adiposity indices and the ratios were included. The QoL of each patient was assessed using the WHOQOL-BREF.</p><p><strong>Results: </strong>The mean ± SD of the age and duration of disease were 49.6± 12.0, and 11.3±8.4 year. 70 out of 75 (93.3%) patients have a DAS-28 score of >2.6. The median values of the transform scores of the WHOQOL-BREF domains were less than 50. There were significant inverse correlations between BMI, and waist-to-height ratio with physical activity (r = -0.167, p = 0.05, and r = -0.168, p = 0.05, respectively). Social domain was significantly and inversely correlated with waist-to-hip, estimated total body fat, and waist-adjusted weight index. A higher BMI and a lower hip index were associated significantly with a lower mean scores of physical health<b>.</b></p><p><strong>Conclusion: </strong>In RA patients, obesity is frequently observed. Over-weight and obese patients had a significantly lower mean score of physical health.</p>","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 2","pages":"247-254"},"PeriodicalIF":0.0,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11350410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}